Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 216159
Company: HIKMA

Products on ANDA 216159

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
MIDAZOLAM IN 0.9% SODIUM CHLORIDE	MIDAZOLAM	50MG/50ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription	AP	No	No
MIDAZOLAM IN 0.9% SODIUM CHLORIDE	MIDAZOLAM	100MG/100ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription	AP	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 216159

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
04/17/2023	ORIG-1	Approval		STANDARD	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216159Orig1s000ltr.pdf

Therapeutic Equivalents for ANDA 216159

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

SOLUTION;INTRAVENOUS; 50MG/50ML (1MG/ML)
TE Code = AP

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
MIDAZOLAM IN 0.9% SODIUM CHLORIDE	MIDAZOLAM	50MG/50ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription	No	AP	216159	HIKMA
MIDAZOLAM IN 0.9% SODIUM CHLORIDE	MIDAZOLAM	50MG/50ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription	Yes	AP	211844	INFORLIFE

SOLUTION;INTRAVENOUS; 100MG/100ML (1MG/ML)
TE Code = AP

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
MIDAZOLAM IN 0.9% SODIUM CHLORIDE	MIDAZOLAM	100MG/100ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription	No	AP	216159	HIKMA
MIDAZOLAM IN 0.9% SODIUM CHLORIDE	MIDAZOLAM	100MG/100ML (1MG/ML)	SOLUTION;INTRAVENOUS	Prescription	Yes	AP	211844	INFORLIFE